Basilea Pharmaceutica AG (BSLN) — Capital Reinvestment Ratio
Basilea Pharmaceutica AG (BSLN) has a Capital Reinvestment Ratio of 0.06x as of December 2025, meaning it reinvests 0% of its operating cash flow (CHF39.03 Million) in capital expenditures (CHF2.30 Million). Check tangible net worth ratio of Basilea Pharmaceutica AG to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Basilea Pharmaceutica AG Capital Reinvestment Ratio (2005–2025)
This chart tracks Basilea Pharmaceutica AG's Capital Reinvestment Ratio across 8 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Basilea Pharmaceutica AG.
Annual Capital Reinvestment Ratio for Basilea Pharmaceutica AG (2005–2025)
Year-by-year Capital Reinvestment Ratio for Basilea Pharmaceutica AG from 2005 to 2025. See BSLN free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CHF) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.04x | CHF62.09 Million | CHF2.62 Million | ▲ +83.5% |
| 2024 | 0.02x | CHF74.36 Million | CHF1.71 Million | ▼ -68.3% |
| 2023 | 0.07x | CHF14.24 Million | CHF1.03 Million | ▼ -84.5% |
| 2022 | 0.47x | CHF7.06 Million | CHF3.30 Million | ▲ +1151.9% |
| 2017 | 0.04x | CHF19.01 Million | CHF711.00K | ▲ +319.3% |
| 2012 | 0.01x | CHF148.17 Million | CHF1.32 Million | ▼ -23.3% |
| 2010 | 0.01x | CHF106.64 Million | CHF1.24 Million | ▼ -66.7% |
| 2005 | 0.03x | CHF34.38 Million | CHF1.20 Million | — |